Skip to main content

Rosetta Genomics FGFR3 Mutation Assays

Rosetta Genomics said today that it will commercially launch two FGFR3 gene mutation assays next week at the American Urological Association annual meeting.

One assay is intended for diagnostic monitoring using urine samples to detect recurrences of FGFR3-positive low-grade bladder cancers, while the other is intended to be used in conjunction with Ki67 expression to tissue-based prognostication at the initial diagnosis of bladder cancer. The microRNA tests are designed to be used in conjunction the company's FISH technology to help urologists better manage patients through improved prognostication and non-invasive recurrence monitoring, Rosetta said.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.